Nektar Therapeutics Reports Q2 2026 Financial Results with $10.1M Revenue and $40.6M Net Loss

Nektar Therapeutics reported its financial results for the second quarter of 2026, revealing a total revenue of $10.1 million, a decrease of 9% from $11.2 million in the same period last year. For the first half of 2026, revenue was $21.0 million, down 3% from $21.6 million in the first half of 2025. The company continues to operate at a loss, with a net loss of $40.6 million for the quarter, slightly improved from a net loss of $41.6 million in the prior year. For the six months ended June 30, 2026, the net loss was $85.5 million, compared to $92.5 million for the same period in 2025.

The company’s operating expenses increased by 11% to $52.5 million for the second quarter, driven primarily by a 31% rise in research and development costs, which totaled $39.1 million. This increase reflects ongoing investments in the development of its lead drug candidate, rezpegaldesleukin, particularly as the company initiated two global registrational trials in July 2026 for moderate-to-severe atopic dermatitis. General and administrative expenses decreased by 25% to $12.8 million, attributed to reduced legal costs.

Nektar's total assets as of June 30, 2026, stood at approximately $1.1 billion, a significant increase from $280.4 million at the end of 2025. This growth is largely due to successful equity financing efforts, which raised $1.07 billion from the sale of shares and pre-funded warrants between July 2025 and April 2026. The company reported cash and investments in marketable securities of $1.02 billion, which it believes will be sufficient to fund operations for at least the next twelve months.

Operationally, Nektar is focused on advancing its pipeline of immunology therapies, with rezpegaldesleukin being evaluated for multiple indications, including atopic dermatitis and alopecia areata. The company is also collaborating with TrialNet to study the drug in patients with new-onset stage 3 Type 1 diabetes mellitus. Nektar's workforce has expanded, with an increase in employee headcount to support its clinical development efforts.

Looking ahead, Nektar anticipates continued investment in its research and development activities, particularly for rezpegaldesleukin, as it progresses through clinical trials. The company acknowledges the inherent risks associated with drug development, including the potential for clinical trial delays and the need for additional financing to support its operations. Nektar remains committed to its strategic direction, focusing on building long-term shareholder value through the advancement of its drug candidates.